MEDI 9287

Drug Profile

MEDI 9287

Alternative Names: Avian influenza vaccine - AstraZeneca; H7N9 vaccine - AstraZeneca; Influenza A virus vaccine H7N9 - AstraZeneca; MEDI-9287

Latest Information Update: 01 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus H7N9 subtype

Most Recent Events

  • 31 Jul 2014 Discontinued - Phase-I for Influenza-A virus H7N9 subtype in USA (unspecified route)
  • 31 Mar 2014 AstraZeneca establishes CRADA with NIH for the development of MEDI 9287 in Influenza A virus H7N9 subtype prior to March 2014
  • 12 Dec 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top